Pentixapharm acquires Glycotope's discovery division

Pentixapharm is enhancing its radiopharmaceutical capabilities by acquiring Glycotope's target discovery business. Although the financial specifics of the acquisition have not been disclosed, the deal includes a portfolio of preclinical antibodies aimed at various oncology markers. These assets are expected to serve as foundational elements for developing a new generation of radiopharmaceuticals.

This acquisition is comprehensive, extending beyond just intellectual property. It includes Glycotope's laboratories, cell banks, and a tumour target database. Additionally, Pentixapharm gains access to multiple patents, licenses, and other tangible assets. The acquisition also involves the integration of a team consisting of 40 executives, R&D specialists, and administrators from Glycotope.

CEO Hakim Bouterfa highlighted the strategic importance of the acquisition, noting that it significantly broadens Pentixapharm's intellectual property portfolio. Until now, the company has primarily focused on the CXCR4 receptor. The acquisition diversifies their research and development efforts, potentially leading to innovative treatments in the field of oncology.

Pentixapharm's current pipeline includes two notable compounds. The first is PentixaFor, a Gallium-68 PET imaging agent designed to target the CXC receptor, which is commonly overexpressed in various types of cancer. This compound is being developed for applications in both oncology and cardiology. The second compound is PentixaTher, a therapeutic agent that complements PentixaFor. PentixaTher is equipped with the high-energy beta emitter Yttrium-90 and is being developed for radioligand therapy specifically targeting blood cancers.

In summary, the acquisition of Glycotope's target discovery business allows Pentixapharm to expand its research and development horizons. With new assets and a specialized team, the company is well-positioned to advance its pipeline and potentially develop novel radiopharmaceutical treatments for cancer.